৳ 350/unit
Pack: ৳ 7,000
৳ 350/unit
Pack: ৳ 7,000
At a glance
Olaparib is a PARP inhibitor used for BRCA-mutated HER2-negative metastatic breast cancer and platinum-sensitive relapsed ovarian cancer. It inhibits PARP enzymes to disrupt DNA repair and cause cancer cell death.
Indications
- BRCA-mutated HER2-negative metastatic breast cancer (previously treated with chemotherapy)
- Platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (maintenance therapy)
Pharmacology
Olaparib inhibits PARP1, PARP2 and PARP3 enzymes to prevent DNA repair. In BRCA-deficient cells with no alternative DNA repair pathways, olaparib causes cell death (synthetic lethality).
Dosage
Adult Dose (Oral):
- Recommended dose: 400 mg (8 x 50 mg capsules) twice daily, total daily 800 mg
- May be taken with or without food
- Continue until disease progression or unacceptable toxicity
Dose Reduction: 200 mg twice daily (total 400 mg/day); further reduce to 100 mg twice daily if needed
Side effects
Common Serious Adverse Reactions:
- Anemia
- Allergic dermatitis
- Decreased neutrophil count
- Decreased platelet count
- Thrombocytopenia
Use in pregnancy
Use in Pregnancy: Olaparib is highly unsafe during pregnancy; teratogenic and embryo-fetal toxicity seen in animal studies. Do not use.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Risk of MDS/AML (<1.5%); discontinue if confirmed
- Do not start until recovery from hematological toxicity from previous chemotherapy (≤ Grade 1)
- Monitor CBC regularly
- Pneumonitis (<1%); discontinue if confirmed
- Can cause fetal harm; use effective contraception
Overdose effects
No specific treatment for overdose; symptomatic supportive measures.
Storage conditions
Store in a dry place below 30°C, protect from light; keep out of reach of children.